Comprehensive Analysis of Genomic Alterations in Chinese High-Grade Serous Ovarian Carcinoma Patients.

Fangfang Zhong,Yu Wang,Rong Shen,Li Zhou,XiaoWei Dong,Xuedong Pan,Lei Mei,Jinwei Hu,Donglin Chen,Weiwei Shi,Xianrong Zhou,Kai Wang
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e17535
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e17535 Background: High-grade serous ovarian carcinoma (HSOC) is a major subtype of ovarian epithelial carcinoma with poor overall survival. It has been previously documented that HSOC has prevalent TP53 mutations and deleterious BRCA1/2 germline mutations. Understanding genomic alterations is critical to improving current therapeutic strategies for HSOC patients (pts). Methods: FFPE and matched normal tissue (26 blood and 20 paracancerous tissue) were collected from 46 Chinese HSOC pts with a median age of 53 years (range 36-82). All cases were reviewed and confirmed by two experienced pathologists. DNA was extracted and ultra-deep NGS was performed on hybridization captured libraries of 450 cancer genes to detect all classes of genomic alterations including substitutions, short and long indels, copy number alterations, and gene rearrangements. Tumor mutational burden (TMB) and microsatellite instability (MSI) status were calculated based on the NGS data. Results: A total of 330 genomic alterations were identified in the 46 HSOC pts, with an average of 7.2 alterations per individual. The top altered genes were TP53 (98%) and BRCA1 (24%), followed by a long tail of genes altered in less than 13% of pts. Five pts (11%) harbored both TP53 and KRAS mutations (two had KRAS G12V, one G12D, one A59G and one D57N). BRCA1/2 mutations were observed in 33% (15/46) pts. Other common altered genes included APC, ERBB2, FAM135B, NF1, PTK2, and RB1. The median TMB was 8.0 mut/Mb (range 0.8-283). Five out of 46 pts were identified as MSI-H (11%). Conclusions: Surprisingly, 5 Chinese HSOC cases (11%) were detected to have both TP53 and KRAS mutations, a much higher percentage than that of TCGA (less than 1%). This might indicate a unique molecular subtype of Chinese HSOC. We also identified a higher proportion of BRCA1/2 mutation carriers (33%) compared with TCGA (22%), suggesting a higher percentage of Chinese HSOC pts might benefit from PARP inhibitors. With the ability to detect all types of genomic alterations, TMB, and MSI at once, NGS-based DNA testing offers a comprehensive understanding of the potential treatment options for ovarian cancer, including targeted therapies and/or immunotherapy such as checkpoint inhibitors.
What problem does this paper attempt to address?